Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Limited Trans Thoracic Echocardiography (L-TTE) by Non-Sonographers Using the UltraSight AI Guidance Software in Hypertrophic Obstructive Cardiomyopathy (HOCM) Patients Eligible for Mavacamten (Camzyos™) Treatment

NCT07155434 is registered in ClinicalTrials.gov with UltraSight as lead sponsor.

NCT NCT07155434
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07155434 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Limited Trans Thoracic Echocardiography (L-TTE) by Non-Sonographers Using the UltraSight AI Guidance Software in Hypertrophic Obstructive Cardiomyopathy (HOCM) Patients Eligible for Mavacamten (Camzyos™) Treatment
Lead sponsor
UltraSight
Phase
Observational
Overall status
Terminated
Start date
July 25, 2025
Completion date
February 24, 2026
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiac imaging, echocardiography, hypertrophic cardiomyopathy (hcm), mavacamten, obstructive cardiomyopathy, hypertrophic